{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:45:13Z","timestamp":1791499513926,"version":"4.3.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG antibodies are developed either by natural infection from SARS-CoV-2 or by vaccination against COVID-19. The persistence of IgG antibodies allows identification of the people who have been infected in the past, recovered from illness, and possibly become immune. 7 IgG detection and other serological assays will play an important role in research and surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objective:<\/jats:title>\n                    <jats:p>The objective of the study is to assess anti-SARS-CoV-2 IgG titre among blood donors and to assess the decreasing incidence of COVID-19 in the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>An observational, cross-sectional study was conducted at the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand over a period of 2 months and 14 days from 06 February 2021 to 20 April 2021 who donated at least one unit of blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This study recorded a greater number of male donors with B+ blood group. The anti-SARS-CoV-2 titre were mostly young adults between 18 and 31 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Seroprevalence was high in males having blood group B+ between 18 and 32 years of age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_727_22","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T05:53:22Z","timestamp":1667973202000},"page":"6385-6389","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi"],"prefix":"10.4103","volume":"11","author":[{"given":"Sushma","family":"Kumari","sequence":"first","affiliation":[{"name":"Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Saroj","sequence":"additional","affiliation":[{"name":"Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Associate Professor, Department of Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/jcm9020498","article-title":"Novel coronavirus outbreak in Wuhan, China, 2020:Intense surveillance is vital for preventing sustained transmission in new locations","volume":"9","author":"Thompson","year":"2020","journal-title":"J Clin Med"},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3855\/jidc.12425","article-title":"2019-nCoV (Wuhan virus), a novel Coronavirus:Human-to-human transmission, travel-related cases, and vaccine readiness","volume":"14","author":"Ralph","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"R5-20260527","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"R6-20260527","year":"2020","journal-title":"Laboratory Testing Strategy Recommendations for COVID-19:Interim Guidance, 21 March 2020"},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tracli.2021.10.004","article-title":"SARS COV-2-IgG antibodies in blood donors in pandemic-A game changer for policy makers","volume":"29","author":"Mahapatra","year":"2022","journal-title":"Transfus Clin Biol"},{"key":"R8-20260527","first-page":"1","article-title":"SARS-CoV-2Seroprevalence among whole blood donors during first wave of covid 19 pandemic in India","volume":"38","author":"Chuchu","year":"2022","journal-title":"Indian J Hematol Blood transfus"},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(20)30544-1","article-title":"SARS-CoV-2 antibody seroprevalence in India, August\u2013September, 2020:Findings from the second nationwide household serosurvey","volume":"9","author":"Murhekar","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R10-20260527","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.abc6810","article-title":"A mathematical model reveals the influence of population heterogenicity on herd immunity to SARS-CoV-2","volume":"369","author":"Britton","year":"2020","journal-title":"Science"},{"key":"R11-20260527","article-title":"Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics","author":"Aguas","year":"2020","journal-title":"medRxiv"},{"key":"R12-20260527","doi-asserted-by":"crossref","first-page":"100056","DOI":"10.1016\/j.lanepe.2021.100056","article-title":"SARSCoV-2 transmission risk from asymptomatic carriers:Results from a mass screening programme in Luxembourg","volume":"4","author":"Wilmes","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"R13-20260527","doi-asserted-by":"crossref","first-page":"2404170","DOI":"10.1155\/2021\/2404170","article-title":"SARS COV-2-IgG surveillance in asymptomtic blood donors and health workers","volume":"2021","author":"Chandra","year":"2021","journal-title":"Adv Med"},{"key":"R14-20260527","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41467-021-21503-x","article-title":"The prevalence of antibodies to SARS COV-2-IgG among blood donors in China","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"R15-20260527","doi-asserted-by":"crossref","first-page":"e0249247","DOI":"10.1371\/journal.pone.0249247","article-title":"Seroprevalence of COVID-19 infection in a rural district of South India:A population-based seroepidemiological study","volume":"16","author":"Inbaraj","year":"2021","journal-title":"PLoS One"},{"key":"R16-20260527","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2021.0332","article-title":"Prevalence of SARS-CoV-2 in Karnataka, India","volume":"325","author":"Mohanan","year":"2021","journal-title":"JAMA"},{"key":"R17-20260527","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2020.12.027","article-title":"Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania","volume":"27","author":"Olariu","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R18-20260527","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/cid\/ciaa849","article-title":"Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors","volume":"72","author":"Erikstrup","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R19-20260527","doi-asserted-by":"crossref","first-page":"104880","DOI":"10.1016\/j.antiviral.2020.104880","article-title":"Lower prevalence of antibodies neutralising SARS-CoV-2 in group O French blood donors","volume":"181","author":"Gallian","year":"2020","journal-title":"Antiviral Res"},{"key":"R20-20260527","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijid.2020.10.011","article-title":"Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody:An up-to-date review","volume":"101","author":"Lai","year":"2020","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_727_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:47Z","timestamp":1786735787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_727_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_727_22","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-03-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}